Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma

被引：0
|
作者：
Agarwala, S. S.
Keilholz, U.
Hogg, D.
Robert, C.
Hersey, P.
Eggermont, A.
Grabbe, S.
Gonzalez, R.
Patel, K.
Hauschild, A.
机构：
[1] St Lukes Hosp & Hlth Network, Bethlehem, PA USA
[2] Charite, Berlin, Germany
[3] Univ Toronto, Toronto, ON, Canada
[4] Inst Gustave Roussy, Villejuif, France
[5] Newcastle Mater Misericordiae Hosp, Newcastle, NSW, Australia
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Univ Klinikum Essen, Essen, Germany
[8] Univ Colorado, Ctr Canc, Aurora, CO USA
[9] Onyx Pharmaceut, Emeryville, CA USA
[10] Univ Kiel, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8510
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
    Hauschild, Axel
    Agarwala, Sanjiv S.
    Trefzer, Uwe
    Hogg, David
    Robert, Caroline
    Hersey, Peter
    Eggermont, Alexander
    Grabbe, Stephan
    Gonzalez, Rene
    Gille, Jens
    Peschel, Christian
    Schadendorf, Dirk
    Garbe, Claus
    O'Day, Steven
    Daud, Adil
    White, J. Michael
    Xia, Chenghua
    Patel, Kiran
    Kirkwood, John M.
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2823 - 2830
  • [2] Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
    Flaherty, Keith T.
    Lee, Sandra J.
    Zhao, Fengmin
    Schuchter, Lynn M.
    Flaherty, Lawrence
    Kefford, Richard
    Atkins, Michael B.
    Leming, Philip
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 373 - 379
  • [3] Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma
    Rao, RD
    Holtan, SG
    Ingle, JN
    Croghan, GA
    Kottschade, LA
    Creagan, ET
    Kaur, JS
    Pitot, HC
    Markovic, SN
    CANCER, 2006, 106 (02) : 375 - 382
  • [4] Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
    Pflugfelder, Annette
    Eigentler, Thomas K.
    Keim, Ulrike
    Weide, Benjamin
    Leiter, Ulrike
    Ikenberg, Kristian
    Berneburg, Mark
    Garbe, Claus
    PLOS ONE, 2011, 6 (02):
  • [5] Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma
    McDermott, D. F.
    Sosman, J. A.
    Hodi, F. S.
    Gonzalez, R.
    Linette, G.
    Richards, J.
    Jakub, J. K.
    Beeram, M.
    Patel, K.
    Cranmer, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
    Yan, Xieqiao
    Sheng, Xinan
    Chi, Zhihong
    Si, Lu
    Cui, Chuanliang
    Kong, Yan
    Tang, Bixia
    Mao, Lili
    Wang, Xuan
    Lian, Bin
    Li, Siming
    Bai, Xue
    Zhou, Li
    Dai, Jie
    Yao, Hong
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (08) : 881 - +
  • [7] Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
    Satoh, Taroh
    Xu, Rui-Hua
    Chung, Hyun Cheol
    Sun, Guo-Ping
    Doi, Toshihiko
    Xu, Jian-Ming
    Tsuji, Akihito
    Omuro, Yasushi
    Li, Jin
    Wang, Jin-Wan
    Miwa, Hiroto
    Qin, Shu-Kui
    Chung, Ik-Joo
    Yeh, Kun-Huei
    Feng, Ji-Feng
    Mukaiyama, Akihira
    Kobayashi, Mikiro
    Ohtsu, Atsushi
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 2039 - U89
  • [8] A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-time treatment of patients with stage III/IV epithelial ovarian cancer
    Hainsworth, J. D.
    Numnum, T. M.
    Rao, G. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer
    Fushida, Sachio
    Kaji, Masahide
    Oyama, Katsunobu
    Hirono, Yasuo
    Nezuka, Hideaki
    Takeda, Toshiya
    Tsukada, Tomoya
    Fujimoto, Daisuke
    Ohyama, Shigekazu
    Fujimura, Takashi
    Ohta, Tetsuo
    ONCOTARGETS AND THERAPY, 2015, 8 : 939 - 941
  • [10] Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer
    Kadowaki, S.
    Izawa, N.
    Minashi, K.
    Nishina, T.
    Yamanaka, T.
    Muro, K.
    Sunakawa, Y.
    Hironaka, S.
    Kajiwara, T.
    Kawakami, Y.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345